Abstract: Provided are graphene nanoribbons with controlled zig-zag edge and cove edge configuration and methods for preparing such graphene nanoribbons. The nanoribbons are selected from the following formulae.

Abstract: The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.

Abstract: The invention relates to a method for producing radiation-curable alkenyl ether polyols, to radiation-curable alkenyl ether polyols produced using the method according to the invention, and to the use thereof for the synthesis of radiation-interlinkable oligomers or polymers by means of polyaddition reactions or polycondensation reactions, in particular for the synthesis of radiation-curable polyesters, polyethers, polyurethanes and polyureas, particularly preferably UV-curable polyurethanes. The invention also relates to radiation-curable polyurethane polymers that are obtained by reacting at least one alkenyl ether polyol according to the invention with a polyisocyanate.

Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

Abstract: A method for deactivating preferably odor-relevant molecules that is distinguished by the following steps is proposed: generating a plasma; deactivating preferably odor-relevant molecules by the effect of hot electrons of the plasma on the molecules to be deactivated.

Abstract: A cross-neutralizing monoclonal antibody that specifically recognizes a cross-reactive epitope of the lipopolysaccharide (LPS) antigen structure of Klebsiella pneumoniae, which is an O3b epitope, cross-reacting with an O3a epitope and an O3 epitope, wherein the antibody is characterized by specific CDR sequences or VH and VL sequences.

Abstract: A method of generating laser pulses (1) includes: creating a circulating light field in resonator device (11) having resonator length L and an intra-cavity dispersion and configured for supporting light field resonator modes, and generating a pulse train of laser pulses (1) by a mode-locking mechanism. Laser pulses (1) are generated with a repetition frequency and provide a frequency comb with carrier frequency ?o and comb modes in frequency space.

Abstract: The present invention relates to a method for producing a panel of cells (i.e. a cell library) expressing various different mutant variants of a protein of interest, wherein only one of said mutant variants is expressed per cell from a single gene copy. The present invention also relates to a method or cell library for identifying a mutant variant of a protein of interest having a different or modified biological activity as compared to the corresponding wild-type protein of interest. According to the present invention the identified mutant variant of a protein of interest may be applied for white biotechnology.

Abstract: An emission lifetime measuring method, in particular for measuring a mean lifetime of electronically excited states of a sample, comprises the steps of illuminating the sample with at least one excitation light pulse, time-resolved detecting an emission response from the sample and creating a temporal detector response function, and calculating the mean lifetime of the electronically excited states on the basis of the detector response function, wherein the at least one excitation light pulse is shaped such that the sample achieves an equilibrium excited steady-state including a linearly increasing or constant number of the electronically excited states, the detector response function has a linear response function section with a constant slope, and the mean lifetime (?) of the electronically excited states is calculated on the basis of at least one of a time position of the linear response function section relative to a reference time of the at least one excitation light pulse and the slope of the linear res

Abstract: A method of image processing of magnetic resonance (MR) images for creating de-noised MR images, comprises the steps of providing image data sets including multiple complex MR images (S7), subjecting the MR images to a wavelet decomposition (S12) for creating coefficient data sets of wavelet coefficients (Sn,m) representing the MR images in a wavelet frequency domain, calculating normalized coefficient data sets of wavelet coefficients Formula (I) (S17), wherein the coefficient data sets are normalized with a quantitative amount of variation, in particular standard deviation Formula (II), of noise contributions included in the coefficient data sets (Sn,m), averaging the wavelet coefficients of each coefficient data set (S18) for providing averaged wavelet coefficients Formula (III) of the coefficient data sets, calculating phase difference maps (??n,m) for all coefficient data sets (S20), wherein the phase difference maps provide phase differences between the phase of each wavelet coefficient and the phase of

Abstract: The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

Abstract: A solution for synchronizing a network comprising a plurality of interconnected nodes provides a stable synchronized state, especially for large scale networks. Signal transmission speed and the length of each interconnection of the network is configured to cause a delay of the signals received by a node from the other node of the interconnection which is larger than one millionth of the free-running period of the controllable oscillator of the receiving node such that Network-wide synchronization of oscillators is achieved for all nodes of the network in a continuous self-organized process in interaction with the other node of the network.

Abstract: In a first aspect, the present invention relates to a method for the purification of virus compositions as well as biological macromolecular compounds in a sample comprising mixing the sample with osmolytes, like non-ionic organic polymers and contacting the mixed sample with a hydrophilic membrane, optionally washing the membrane,and eluting the virus preparations or biological macromolecular components from the membrane with an eluting solution containing reduced amounts or no osmolytes, like non-ionic organic polymer. Moreover, virus compositions and biological macromolecular components obtainable with the method according to the present invention are provided as well as the use of the method according to the present invention for purification of virus compositions including whole virus particles and virus-like particles or biological macromolecular components.

Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

Abstract: The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD+, NADP+ and/or the ratios of the concentrations of NAD+/NADH and NADP+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.

Abstract: The present invention relates to a method for predicting a treatment response to a corticotropin releasing hormone receptor type 1 (CRHR1) antagonist and/or a vasopressin receptor 1B (V1B) antagonist in a patient with depressive and/or anxiety symptoms. The present invention furthermore relates to a V1B receptor antagonist and/or CRHR1 antagonist for use in the treatment of depressive symptoms and/or anxiety symptoms in a patient. Also, kits, diagnostic compositions, devices and microarrays allowing the determination of the presence or absence of at least one polymorphic variant in the AVPR1B gene in combination with the presence or absence of at least one polymorphic variant in the patient's genome excluding the AVPR1B gene in the nucleic acid sample are described.

Abstract: The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

Abstract: Optical component (10) for modulating light field (1) incident thereon, particularly amplitude and/or phase in dependency on intensity (I) thereof, includes stack (11) of refractive layers (12, 13) on substrate (14), made of materials having third-order nonlinearity, and having alternatingly varying refractive indices (n), including linear contribution (n0) and non-linear contribution (n2), and determining reflectance and transmittance spectra of the optical component, wherein refractive layers (12, 13) are configured such that reflectance and transmittance of the optical component have a Kerr effect based dependency on intensity (I) of the incident light field with n=n0+I·n2, and refractive layers (12, 13) are made of at least one of dielectric and semiconductor layers, wherein non-linear contribution (n2) is below 10?12 cm2/W. A resonator device including the optical component, a method of modulating a light field using the optical component and a method of manufacturing the optical component are described.

Abstract: Compounds of formula I are disclosed: wherein X1, X2, X3, X4 are independently H, F, Cl, Br, I, CN, NO2, OR1, SR1, NR1R2, COR1, COOR1, CONR1R2, PO3R1R2, SO2R1, SO3R1 or R3; R1 and R2 are, e.g., H, alkyl or aryl or optionally a ring; R3 is, e.g., alkyl, alkenyl, alkynyl, aryl or cycloalkyl; Y is OR1, NR1R2, or NR1R3; Q is O, S, SO2, NR, C(R3)2, Si(R3)2, Ge(R3)2, P(?O)R3 or P(?O)OR3; Q and X1 can optionally form part of a ring; L and M are independently OR1, SR1, NR1R2 and R3; L and M can optionally form part of a ring; Z is O, S, NR1, CR1R3 or aryl; and Z and X4 can optionally form part of a ring.

Abstract: The invention relates to an MRI apparatus for magnetic resonance imaging of a subject of investigation, comprising: a coil arrangement (1) for transmitting an excitation signal into the subject and for receiving a response signal from the subject; a high-power radio-frequency amplifier (4) for generating the excitation signal; and a low-noise amplifier (LNA) for amplifying the response signal. The invention provides a transmit/receive switch (5) which is alternatively operable in a transmit mode or in a receive mode. In the transmit mode, the transmit/receive switch (5) transmits the excitation signal to the coil arrangement (1) and protects the low-noise amplifier (LNA) from the outgoing excitation signal. In the receive mode, the transmit/receive switch (5) routes the in coming response signal to the low-noise amplifier (LNA).